Genital Herpes: Episodic and Suppressive Antiviral Therapy

Diagnosis and clinical assessment

Painful grouped vesicles or shallow ulcers may suggest genital HSV, but morphology is not reliable enough to establish HSV type. Obtain HSV-1/HSV-2 NAAT from an active lesion when available. Type-specific serology may clarify selected diagnostic questions but is not a substitute for lesion testing; avoid routine low-value screening. Evaluate concurrent syphilis and other STIs, urinary retention, neurologic complaints, and disseminated infection. HSV-1 and HSV-2 have different typical recurrence patterns (Smith & Honeywell, 2026).

First clinical episode

For adults with a first clinical episode, a common regimen is valacyclovir 1 g orally twice daily for 7–10 days; acyclovir 400 mg orally three times daily for 7–10 days is an alternative. Extend treatment if healing is incomplete. Severe disseminated, neurologic, or otherwise complicated infection may require IV acyclovir and inpatient management. Adjust renal dosing when necessary and counsel on hydration and adverse effects (Smith & Honeywell, 2026).

Recurrent episodic therapy

Give a prescription to start promptly, ideally during prodrome or within one day after symptoms appear. Shorter regimens are effective, such as valacyclovir 500 mg orally twice daily for three days or valacyclovir 1 g orally daily for five days. Choice depends on frequency, access, prior response, and renal function. An antiviral started after the outbreak has largely resolved may offer little additional benefit (Smith & Honeywell, 2026).

Suppression and transmission reduction

For frequent or distressing recurrences, options include valacyclovir 500 mg once daily, valacyclovir 1 g once daily, or a suitable acyclovir regimen. Valacyclovir 500 mg daily may be less effective in very frequent recurrences. Suppression can also reduce transmission of HSV-2 in selected discordant partnerships, but it does not eliminate risk. Discuss condoms, avoiding sexual contact during prodrome or lesions, partner disclosure, and asymptomatic shedding. Reassess whether daily suppression remains useful as recurrence frequency changes (Smith & Honeywell, 2026).

Pregnancy and other special populations

A genital lesion or prodrome at the time of labor requires obstetric evaluation because neonatal HSV risk is consequential. Pregnancy suppressive treatment near term and delivery decisions follow obstetric protocols. Immunocompromised patients may require higher doses or longer courses and evaluation for antiviral resistance. Avoid stigmatizing language; explain latency, variable recurrence, and expected response clearly.

Deciding between episodic and daily suppression

For a first clinical episode, oral valacyclovir 1 g twice daily for 7–10 days differs from recurrent episodic treatment (eg, 500 mg twice daily for three days or 1 g daily for five days). An episodic prescription should be available before or at the first prodrome so that treatment is timely. Daily suppression is reasonable when recurrences, distress, or transmission concerns justify ongoing medication, but the regimen depends on episode frequency and patient factors. Choose among acyclovir, valacyclovir, and famciclovir using administration burden, renal function, and cost; they do not eliminate latency (Smith & Honeywell, 2026).

Clinical situations that change the treatment site

Severe disseminated disease, neurologic findings, or inability to take oral medication can require IV acyclovir and inpatient evaluation. In pregnancy, coordinate labor/delivery prevention planning and late-gestation suppression through obstetric guidance; do not apply routine nonpregnant episodic schedules uncritically. In resistant or highly immunocompromised cases, pursue specialist evaluation and appropriate resistance testing. Renal dysfunction requires agent-specific adjustment, particularly to prevent acyclovir-related neurotoxicity or nephrotoxicity (Smith & Honeywell, 2026).

Clinical application

A patient with confirmed HSV-2 has eight outbreaks per year, reduced eGFR, and a partner without known HSV infection. Compare convenient once-daily suppression with self-started episodic therapy based on recurrence burden and transmission concerns; select a renal-adjusted antiviral using current dosing tables. Provide barrier/abstinence counseling during symptoms and annual reassessment of whether suppression remains desired. A new severe headache, confusion, or disseminated lesions would trigger urgent evaluation rather than simply increasing the oral dose (CDC, 2021, Genital Herpes; Smith & Honeywell, 2026).

High-yield distinctions

The first episode is not synonymous with recent acquisition. Antivirals suppress HSV rather than eradicate latency. Dosing differs sharply for initial, episodic, and suppressive therapy.

Related YourDNP Resources

Pharmacology learning hub · Syphilis · Chlamydia and genital warts · Less-common STIs

---

---

References

Centers for Disease Control and Prevention. (2021). Genital herpes. https://www.cdc.gov/std/treatment-guidelines/herpes.htm

Smith, U. D., & Honeywell, M. S. (2026). Sexually transmitted infections. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 83). McGraw Hill.